Loading...
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
Early results of a prospective phase 2 clinical trial of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance in high-risk smoldering myeloma showed promising results that were previously published. Here, we provide novel insights into the genetic landscape of high-risk...
Na minha lista:
| Udgivet i: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728141/ https://ncbi.nlm.nih.gov/pubmed/29296837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017005934 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|